KRAS and cancer: For example, molecules that disrupt the CXCR1/2-MDSC axis may be combined with ICIs and KRAS/or SHP2 inhibitors to reverse MDSC-mediated immunosuppression.301,302 Other combinations of SHP2, KRAS, and IC inhibitors may also reshape the TME and suppress the adaptive signaling of cancer cells, which diminishes sensitivity to KRASG12C inhibition.207,303,304